Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Epacadostat in Muscle-invasive Bladder Cancer
NCT03832673Phase 2Withdrawn
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- May 2019
- Primary completion
- May 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epacadostat and pembrolizumab in muscle-invasive bladder cancer (MIBC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Pathologic complete response at 12 months. Planned start May 2019; status: withdrawn.
02
Drugs
epacadostatpembrolizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT03832673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03832673.